Form 8-K - Current report:
SEC Accession No. 0001493152-25-008080
Filing Date
2025-02-24
Accepted
2025-02-24 17:18:24
Documents
17
Period of Report
2025-02-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51163
2 ex10-1.htm EX-10.1 33267
3 ex10-2.htm EX-10.2 19231
4 ex10-2_001.jpg GRAPHIC 14869
  Complete submission text file 0001493152-25-008080.txt   315690

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE aneb-20250220.xsd EX-101.SCH 3012
6 XBRL LABEL FILE aneb-20250220_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE aneb-20250220_pre.xml EX-101.PRE 22357
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3818
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 25658216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)